Finance
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
C
CNBC
April 30, 2026·1 min read
GM
FinanceIf that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
Original article
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
Published by CNBC